Publications
35
Citations
519
Est. group size
—
Recurring co-author estimate
Active years
11
Publishing since 2015
Megan L. Noonan conducts biomedical research focused on kidney biology and bone/skeletal biology in mouse models. Recent work examines how kidney cells respond to injury and repair, including the role of RNA processing (alternative splicing) in driving inflammation, using advanced sequencing methods. Earlier work addressed bone quantity, fracture repair, and hormone-related disorders such as parathyroid and fibroblast growth factor signaling.
Publication activity peaked around 2020 and has since settled into a steadier, more moderate output of roughly a few papers per year.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Long-Read Single-Cell RNA Sequencing Reveals the Alternative Splicing Landscape across Mouse Kidney Epithelial Cells
Journal of the American Society of Nephrology · 2024
- Identification of Human Pathways Acting on Nuclear Non-Coding RNAs Using the Mirror Forward Genetic Approach
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Injury-induced Foxm1 expression in the mouse kidney drives epithelial proliferation by a cyclin F–dependent mechanism
JCI Insight · 2024
- Long-Read Sequencing Identifies Loss of Proximal Tubule Spliceosome Gene Srsf7 as a Driver of Inflammation Through Alternative Splicing
Journal of the American Society of Nephrology · 2023
- Mice Lacking the a2d1 Auxiliary Voltage Sensitive Calcium Channel Subunit Have Impaired Bone Quantity and Decreased Lean Mass
2017
- Biglycan potentially regulates angiogenesis during fracture repair by altering expression and function of endostatin
Matrix Biology · 2016
- Journal of the American Society of Nephrology×6
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Frontiers in Endocrinology×2
- JCI Insight×2
- Physiological Reports×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile